Innate Pharma (IPHA) Current Assets (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Current Assets data on file, last reported at $54.4 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 40.66% year-over-year to $54.4 million; the trailing twelve-month figure through Dec 2025 stood at $54.4 million (down 40.66% YoY), and the FY2025 full-year result was $54.4 million, down 40.66% from the prior year.
• Current Assets for Q4 2025 stood at $54.4 million, down from $73.6 million in the prior quarter.
• Across five years, Current Assets topped out at $183.3 million in Q2 2022 and bottomed at $54.4 million in Q4 2025.
• The 5-year median for Current Assets is $149.4 million (2021), against an average of $129.7 million.
• The widest annual swing landed in 2021, when Current Assets slumped 99.9%; it then gained 17.38% in 2022.
• A 5-year view of Current Assets shows it stood at $158.2 million in 2021, then slipped by 9.8% to $142.7 million in 2022, then advanced by 11.63% to $159.3 million in 2023, then sank by 42.47% to $91.6 million in 2024, then slumped by 40.66% to $54.4 million in 2025.
• The last three Current Assets figures came in at $54.4 million (Q4 2025), $73.6 million (Q2 2025), and $91.6 million (Q4 2024), per Business Quant data.

Peer Comparison